Technical Data
I0100-15
I-309, Recombinant, Human
2ug
10ug
10ug
|
Technical Data |
|
I0100-15 |
I-309, Recombinant, Human |
2ug 10ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: RT |
|
The human cytokine I-309 is a small glycoprotein secreted by activated T lymphocytes and structurally related to a number of inflammatory cytokines. Recombinant Human I-309 is a single,non-glycosylated, polypeptide chain containing 74 amino acids and having a molecular mass of 8.504kD. Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Ser-Lys-Ser-Met-Gln. Dimers and Aggregates: 1% as determined by silver-stained SDS-PAGE gel analysis. Biological Activity: Human I-309 is fully biologically active when compared to standard. The Biological activity is calculated by its ability to chemoattract human T cells at 10.0-100.0ng/ml. Endotoxin: 0.1ng/ug (IEU/ug) of Human HCC-1. Protein Content: Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm. 2. Analysis by RP-HPLC, using a calibrated solution of Human I-309 as a Reference Standard. Reconstitution: Reconstitute the lyophilized Human I-309 in sterile 18MO-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions. Storage and Stability: Lyophilized powder may be stored at 4°C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer. |
Source: E. coli Purity: 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Concentration: ~0.1mg/ml Form: Supplied as a lyophilized powder. No additives. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Human cord blood-derived mast cells synthesize and release I-309 in response to IgE. Gilchrest H, Cheewatrakoolpong B, Egan RW, Life Sci 2003 Oct 3;73(20):2571-81 2. CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I. Louahed J, Struyf S, Parmentier M, Eur J Immunol 2003 Feb;33(2):494-501 3. Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309. Ruckes T, Saul D, Hermine O, Blood 2001 Aug 15;98(4):1150-9 4. Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309. Inngjerdingen M, Damaj B, J Immunol 2000 Apr 15;164(8):4048-54 5. The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned medium. Haque NS, Fallon JT, Harpel PC, Blood 2001 Jan 1;97(1):39-45 6. I-309 binds to and activates endothelial cell functions and acts as an angiogenic molecule in vivo. Bernardini G, Spinetti G, Camarda G, Capogrossi MC, Blood 2000 Dec 15;96(13):4039-45.
|
||